TREATMENT PATTERNS AND PROGNOSIS OF PATIENTS WITH AN INCIDENT DRUG-INDUCED PARKINSONISM
Author(s)
Kim S1, Suh HS2
1Pusan National University, Busan, South Korea, 2Pusan National University, Busan, Korea, Republic of (South)
Presentation Documents
OBJECTIVES To explore changes in treatment patterns and prognosis after an incident drug-induced parkinsonism (DIP) in South Korea METHODS In this retrospective cohort study, we used the National Health Insurance Service―National Sample Cohort database between 2002 and 2013. Based on previous studies and expert opinions of Korean neurologists, we identified patients with DIP who had (1) ≥1 claim with diagnosis code for DIP between 2007 and 2011; and (2) an outpatient prescription for offending drugs which overlapped with the date of the earliest claim with diagnosis code for DIP, which was designated as the index date. We excluded patients who had DIP within 5 years before the index date to assure incident DIP. Offending drugs, which are frequently associated with DIP, included propulsives (e.g., metoclopramide and levosulpiride), antipsychotics, and flunarizine. We assessed the first changes in treatment patterns (switching, dose adjustment, reinitation, discontinuation, and persistent use) of offending drugs and the prognosis of DIP during the two years after the index date. Remittance was defined as an absence of new DIP diagnosis over 4 months. RESULTS Among 110 patients with an incident DIP, 40.0% were male and 57.3% were aged ≥65 years. Offending drugs were propulsives (68.2%), antipsychotics (28.2%), and flunarizine (3.6%). After DIP occurrence, the most common modification in offending drugs was switching to other offending drugs (35.5%), followed by dose adjustment (23.6%), reinitiation after a temporary discontinuation (21.8%), discontinuation (16.4%), and persistent use (2.7%). For each drug class, propulsives showed high proportion of switching (42.7%) while antipsychotics showed high proportion of discontinuation (32.3%). DIP remitted in 82.7%, recurred in 11.8%, and persisted in 5.5% of all patients. CONCLUSIONS In South Korea, DIP is managed by treatment modification such as switching, dose adjustment, and discontinuation. Careful management is needed in patients experiencing recurrence or persistence of DIP symptoms.
Conference/Value in Health Info
2019-05, ISPOR 2019, New Orleans, LA, USA
Value in Health, Volume 22, Issue S1 (2019 May)
Code
PND53
Topic
Epidemiology & Public Health, Health Service Delivery & Process of Care
Topic Subcategory
Safety & Pharmacoepidemiology, Treatment Patterns and Guidelines
Disease
Neurological Disorders